Some lawmakers even called on the FDA to probe the commercial. Novo Nordisk, maker of branded GLP-1 treatments, has now countered with an ad of its own. The ad, placed in major newspapers ...

I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest fitness gadgets, testing out activewear and sneakers, as well as debunking wellness myths. On my spare time I enjoy ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

After hours: 7:59:01 p.m. EST ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Bonus Sep 15, 2005 Sep 17, 2005 Jul 18, 2005 Bonus Ratio: 1 share(s) for every 2 shares held Rights Jan 09, 1995 Feb 01, 1995 Mar 15, 1995 Rights ratio: 1 share for every 1 held at a price of Rs 40.0 ...